Ilana Meyer is a member of Foley & Lardner’s Health Care Practice Group. She began at Foley as a summer associate. While in law school, she worked as a Judicial Intern for Senior Judge Paul L. Friedman of the United States District Court for the District of Columbia. Most recently, Ilana interned in the Office of General Counsel for the Dana-Farber Cancer Institute working on regulatory and policy issues. She also has experience within a multidisciplinary team, performing complex clinical ethics consultations.
Presentations and Publications
- Co-author, “Massachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry,” Health Care Law Today (August 5, 2024)
- Co-author, “Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use,” Health Care Law Today (March 13, 2024)
Massachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry
The Massachusetts legislative session officially closed on August 1, 2024 after an unusual half day extension.
What Does the End of Chevron Deference Mean for Federal Health Care Programs?
On June 28, 2024, the Supreme Court rejected the doctrine of Chevron deference in the closely watched case of Loper Bright Enterprises v. Raimondo.
Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use
In February 2024, the U.S. Food and Drug Administration published its finalized guidance concerning its investigational drug charging regulations.